Pushkal Garg

EVP Chief R&D

Pushkal Garg (EVP Chief R&D) filed 5 Form 4 reports in the trailing twelve months (0 purchases, 5 sales), most often in Alnylam Pharmaceuticals, Inc. (ALNY). The largest single filing was $2.3M of ALNY (5,170 sh across 10 lots, as filed), executed Oct 2 2025.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 5 sells

Median delay

–

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$6.4M

shares × price, as filed

Last traded

Mar 5

Filed Mar 6

Median ADV $470.9M across their filed names

Open performance→

Volume by month

Buys $0 Sells $26.3M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 5 filings

Sector per market data · by filing · past 12 months

Most traded names

ALNY

Alnylam Pharmaceuticals, Inc. ALNY · 0 buys · 12 sells 12 filings

Recent filings

ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $216K
862 sh × $250.11
Exec Feb 18 2025
Filed Feb 18 2025 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $15.0M
52,592 sh × $285.00
Exec Jan 27 2025
Filed Jan 29 2025 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $302K
1,204 sh across 2 lots
Exec Dec 12 2024
Filed Dec 13 2024 · 5:30 PM ET ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $238K
945 sh × $251.42
Exec Nov 26 2024
Filed Nov 27 2024 · 5:30 PM ET